GTBP GT Biopharma: חובות לטווח קצר של החברה

GT Biopharma, Inc. (GTBP) generates revenue by developing immunotherapeutic agents that activate killer cells to destroy tumors. A lack of sales and the current trial stage lead to total capital depletion, precluding a stable cash flow. The proprietary bispecific antibody platform creates a potential moat, yet regulatory risks pressure margins. The indicator stands at 0.00, which is clearly demonstrated by the asset's market value dynamics at the bottom of the page.

To assess the solvency of GT Biopharma, Inc. (GTBP), investors must analyze the total amount of all liabilities maturing within one year, which determines current liquidity and default risk. The trend in short-term loan debt reflects the company's ability to fund the costly development of the TriKE platform under strict FDA oversight, where any sharp spike on the chart signals a critical dependence on external venture capital.